The global bone growth stimulators market size was valued at USD 1,492.13 million in 2022. It is estimated to reach USD 2,255.92 million by 2031, growing at a CAGR of 4.7% during the forecast period (2023–2031).
Bone growth stimulation is an alternative bone healing treatment recently gaining popularity. Bone stimulators are frequently used to treat fractures that cannot heal naturally. The prevalence of bone fractures and sports injuries is gradually increasing, increasing the demand for bone growth stimulators worldwide. Bone growth stimulation devices and products have positively influenced orthopedic procedures.
The market potential for bone morphogenetic protein has prompted multiple clinical studies. These stimulators have various uses, including spinal fusion, dental, maxillofacial, and fracture repair. The increasing prevalence of osteoarthritis and degenerative bone diseases also increases the market's growth. The market is expected to experience growth as a result of the increased utilization and demand for bone morphogenetic proteins and platelet-rich plasma factors, which have been shown to enhance healing outcomes.
The growing preference for adopting non-invasive bone growth stimulators is expected to drive the market during the forecast period. Non-invasive stimulators use ultrasonic, electrical signals, magnetic, or to stimulate osteogenesis with a spinal fusion or fracture fixation. The equipment is positioned above the fracture site for a specified duration during the treatment.
Furthermore, the growing prevalence of bone diseases globally is expected to drive the market during the forecast period. Rising cases of osteoporosis are expected to be the leading cause of fractures worldwide during the forecast period. Rising diagnoses of such conditions and rapid technological advancement for improved treatment will drive market growth in the coming years. The rising oral and maxillofacial surgeries worldwide will also support the industry's growth during the forecast period.
Industry growth in the coming years is anticipated to be spurred by the rising incidence of bone and joint disorders. Bone growth stimulators have benefited from the rising demand for spinal fusion and oral and maxillofacial surgeries among the aging population caused by this disease. Osteoarthritis and other joint disorders are common in the over-65 aged population. In addition, the prevalence of arthritis is expected to increase in the coming years as the population ages. In the United States, the CDC estimates that the number of people with doctor-diagnosed arthritis will reach 78.4 million by 2040. As per global estimates by the World Health Organization (WHO), approximately 18% of women and 9.6% of men aged 60 and above experience symptomatic osteoarthritis.
Similarly, lumbar spondylosis is also a common condition, affecting over 79% of people over 40 in the United States. Bone growth stimulators are a treatment option for these conditions, as they can reduce intraosseous venous congestion and remodel bone. With the rise in the prevalence of these diseases, there will be a corresponding surge in the demand for bone growth stimulators.
Rising healthcare costs and an aging population present difficulties for the healthcare system. Medical reimbursement is among the most important factors influencing their uptake and demand regarding diagnostic or therapeutic products. In many cases, private health insurance will not cover the price of bone growth stimulation procedures. For instance, due to insufficient clinical data on its therapeutic efficacy, most healthcare insurance providers worldwide (aside from the US) do not cover the cost of plasma therapy. This could be a hindrance to the sales of bone growth stimulators.
Platelet-rich plasma (PRP) is a blood-based therapy that treats various orthopedic conditions such as musculoskeletal injuries, arthritis, and chronic tendinitis. Platelets from a patient's blood are extracted and concentrated to make PRP. Growth factors in platelets aid in tissue repair and regeneration. In addition, PRP therapy is widely regarded as a safe and efficient treatment for various orthopedic disorders. It is less invasive than surgery and has fewer side effects.
PRP therapy is also relatively quick and easy to apply. In addition to orthopedic conditions, PRP therapy is used to treat various conditions such as cardiac muscle injuries, nerve injuries, and periodontal surgeries. In the upcoming years, PRP clinical applications are anticipated to increase. The rising number of orthopedic conditions, the safety and efficacy of PRP therapy, and the growing demand for minimally invasive treatments are all encouraging the PRP market forward.
The global bone growth stimulators market is bifurcated into product, application, and end-user.
Based on the product, the global bone growth stimulator market is divided into bone growth stimulation devices, bone morphogenetic proteins (BMP), and platelet-derived growth factor (PDGF).
The bone growth stimulation devices segment is the highest contributor to the market share and is expected to grow at a significant rate during the forecast period. The devices segment is anticipated to be driven during the forecast period by an increase in the use of portable, battery-powered bone growth stimulators for the treatment of non-union fractures, as well as an increase in the adoption of external bone growth stimulators. In addition to bone growth devices, manufacturers are increasing the production of bone glues and bone cement to increase the availability of supplemental bone healing products.
Based on application, the global bone growth stimulators market is divided into spinal fusion surgeries, delayed union and nonunion bone fractures, oral and maxillofacial surgeries, and others.
The spinal fusion surgeries segment owns the largest market share and is anticipated to grow at a significant rate during the forecast period. Spinal fusion surgeries brought in the most money for the healthcare industry. Demand for spinal fusion surgeries has skyrocketed worldwide due to the growing prevalence of spinal cord injuries like fractures, spinal stenosis, and herniated discs. The World Health Organization estimated that 300,000 and 550,000 people sustain spinal cord injuries yearly, mostly due to traffic accidents, falls, and acts of violence.
Based on end-user, the global bone growth stimulators market is divided into hospitals and clinics, academic and research institutes and CROs, home care, and others.
The hospital and clinic segment dominates the global market and is estimated to grow at a significant rate during the forecast period. The hospital sector strongly holds the global market because many people go to hospitals for medical care and orthopedic procedures. This dominance is further strengthened by the fact that there are many hospitals worldwide in both developed and developing markets. Government hospitals are very important in several markets, especially in emerging economies, because they offer subsidized care, which also helps this segment to be the most important.
In developed markets, a big trend is the rise of specialty clinics focusing on specific medical fields like orthopedics. Bone fractures are complex injuries that require specialized treatment, which is expected to boost business for specialty clinics over the next few years.
Based on region, the global bone growth stimulators market is bifurcated into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
North America Dominates the Global Market
North America is the most significant shareholder in the global bone growth stimulators market and is expected to grow at a significant rate over the forecast period. North America holds the biggest share of the bone growth stimulators market in 2022, with about 35%. This is mostly because of the rising number of older people and the rising number of spinal cord injuries in North America. As per the National spinal cord injury statistical center report, there are approximately 54 cases of spinal cord injury (SCI) per one million people, resulting in approximately 17,900 new spinal cord injury cases each year in the U.S. Therefore, the regional bone growth stimulator market is expected to grow rapidly during the forecast period.
Europe is predicted to grow at significant rate during the forecast period. This is because Europe has an aging population, more people are getting orthopedic problems, and more people know about the benefits of bone growth stimulators. One of the most common orthopedic problems in Europe is osteoarthritis. It happens when cartilage in the joints breaks down, causing pain, stiffness, and a limited ability to move. Most often, it affects the knee, hip, and hand joints. Rising orthopedic fixation treatment patients, high awareness among the European people, and high spending income are numerous factors driving the market's growth in Europe.
In Asia-Pacific, the bone growth stimulators market is expected to present significant growth opportunities during the forecast period. Bone growth stimulators are becoming more affordable due to rising healthcare investment by the major players in the Asia-Pacific region. This will bring up new business opportunities in the region that manufactures and distribute bone growth stimulators.
Latin America and the Middle East and Africa are the smaller markets for bone growth stimulators, but they are expected to grow at a significant rate over the forecast period. The LAMEA market growth is due to the rising prevalence of orthopedic disorders and the rising number of road accidents and trauma cases. Thus, the rising number of road accidents in Latin America, and the Middle East, and Africa region boosts the growth of the market.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
"Find new revenue generation opportunities"